Comparative Pharmacology
Head-to-head clinical analysis: DASETTA 1 35 versus TRI LO ESTARYLLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DASETTA 1 35 versus TRI LO ESTARYLLA.
DASETTA 1/35 vs TRI-LO-ESTARYLLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of an estrogen (ethinyl estradiol) and a progestin (norethindrone). Suppresses gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, induces changes in cervical mucus (impenetrability to sperm) and endometrium (reduced likelihood of implantation).
Combination oral contraceptive containing ethinyl estradiol and norgestimate. Suppresses gonadotropin secretion, primarily FSH and LH, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial lining, reducing implantation likelihood.
One tablet orally once daily, each containing 1 mg norethindrone acetate and 35 mcg ethinyl estradiol.
One tablet (20 mcg ethinyl estradiol/0.1 mg levonorgestrel) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Norethindrone: 5-14 hours (mean 8 hours); ethinyl estradiol: 10-20 hours (mean 14 hours). Clinical context: steady-state achieved within 5-7 days.
Ethinyl estradiol: 19-24 hours (terminal); Norgestimate: active metabolite norelgestromin 28-38 hours; allows once-daily dosing.
Renal (55-60% as metabolites, 25-30% as unchanged drug and conjugates), biliary/fecal (30-35% as metabolites).
Renal: ~40% as metabolites; Fecal: ~30% as metabolites (including ethinyl estradiol conjugates); Biliary: ~20% (enterohepatic recirculation).
Category C
Category C
Oral Contraceptive
Oral Contraceptive